Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine

Summary

This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60. Participants will receive three intramuscular injections of either adjuvanted AV-1959R (100 µg or 300 µg) or adjuvanted placebo at Weeks 0, 4, and 14, followed by an 8-week follow-up. Researchers will monitor for side effects and measure anti-Aβ antibody levels to assess immune response. This study will help determine if AV-1959R is safe and effective in generating a targeted immune response.

Timeline

Start

2024-06-12

Primary completion

2025-12-01

Completion

2025-12-01

Drugs

Indications